Compare ARCB & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARCB | GPCR |
|---|---|---|
| Founded | 1923 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 1994 | 2023 |
| Metric | ARCB | GPCR |
|---|---|---|
| Price | $122.36 | $38.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $122.75 | $103.17 |
| AVG Volume (30 Days) | 325.4K | ★ 772.9K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,657,864,000.00 | N/A |
| Revenue This Year | $7.00 | N/A |
| Revenue Next Year | $5.80 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.56 | N/A |
| 52 Week Low | $59.43 | $15.80 |
| 52 Week High | $135.10 | $94.90 |
| Indicator | ARCB | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 58.85 | 32.35 |
| Support Level | $115.28 | $30.82 |
| Resistance Level | $135.10 | $40.29 |
| Average True Range (ATR) | 5.50 | 2.34 |
| MACD | -1.23 | 0.06 |
| Stochastic Oscillator | 50.91 | 16.92 |
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.